FDA looks at Avastin risks
 

The US Food and Drug Administration is holding a two-day hearing that pits the FDA's Center for Drug Evaluation and Research against Genentech, that manufactures breast cancer drug Avastin. A handful of breast cancer patients testified Tuesday that Avastin helped in treating their metastatic breast cancer but a review of studies conducted by the FDA's Center for Drug Evaluation and Research suggests the risks outweigh the benefits of Avastin for treating breast cancer, FDA officials said at the hearing.

More...